The FERM family proteins in cancer invasion and metastasis

Frontiers in Bioscience

Volumn 16, Issue 4, 2011, Pages 1536-1550

  Yu, Hefen ^a,b   Zhang, Yuxiang ^a   Ye, Lin ^b   Jiang, Wen G ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

4.1B; Ehm2; Ezrin; FAK; FERM protein; Invasion; Merlin; Metastasis; Moesin; Radixin; Review

Indexed keywords

ACTIN BINDING PROTEIN; CYTOSKELETON PROTEIN; DNA BINDING PROTEIN; EPB41L4B PROTEIN, HUMAN; ETV5 PROTEIN, HUMAN; EZRIN; FOCAL ADHESION KINASE; MEMBRANE PROTEIN; MERLIN; MOESIN; PROTEIN 4.1B, HUMAN; TRANSCRIPTION FACTOR;

CANCER INVASION; CELL COMMUNICATION; HUMAN; METASTASIS; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CELL COMMUNICATION; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; MEMBRANE PROTEINS; MICROFILAMENT PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEUROFIBROMIN 2; TRANSCRIPTION FACTORS;

EID: 79955040874     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3803     Document Type: Article

References (135)

1. A. Ahmad and I. R. Hart: Mechanisms of metastasis. Crit Rev Oncol Hematol, 26(3), 163-73 (1997) (Pubitemid 28066441)
2. T. Cavanna, E. Pokorna, P. Vesely, C. Gray and D. Zicha: Evidence for protein 4.1B acting as a metastasis suppressor. J Cell Sci, 120(Pt 4), 606-16 (2007) (Pubitemid 46437895)
3. P. S. Steeg: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med, 12(8), 895-904 (2006) (Pubitemid 44175140)
4. C. X. Sun, V. A. Robb and D. H. Gutmann: Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation. J Cell Sci, 115(Pt 21), 3991-4000 (2002) (Pubitemid 35446798)
5. J. M. Tyler, W. R. Hargreaves and D. Branton: Purification of two spectrin-binding proteins: biochemical and electron microscopic evidence for site-specific reassociation between spectrin and bands 2.1 and 4.1. Proc Natl Acad Sci U S A, 76(10), 5192-6 (1979) (Pubitemid 10236105)
6. T. L. Leto and V. T. Marchesi: A structural model of human erythrocyte protein 4.1. J Biol Chem, 259(7), 4603-8 (1984) (Pubitemid 14131368)
7. K. A. Shiffer and S. R. Goodman: Protein 4.1: its association with the human erythrocyte membrane. Proc Natl Acad Sci U S A, 81(14), 4404-8 (1984) (Pubitemid 14052454)
8. A. Bretscher: Purification of the intestinal microvillus cytoskeletal proteins villin, fimbrin, and ezrin. Methods Enzymol, 134, 24-37 (1986)
9. S. Tsukita and Y. Hieda: A new 82-kD barbed endcapping protein (radixin) localized in the cell-to-cell adherens junction: purification and characterization. J Cell Biol, 108(6), 2369-82 (1989) (Pubitemid 19168926)
10. W. T. Lankes and H. Furthmayr: Moesin: a member of the protein 4.1-talin-ezrin family of proteins. Proc Natl Acad Sci U S A, 88(19), 8297-301 (1991) (Pubitemid 21915343)
11. A. H. Chishti, A. C. Kim, S. M. Marfatia, M. Lutchman, M. Hanspal, H. Jindal, S. C. Liu, P. S. Low, G. A. Rouleau, N. Mohandas, J. A. Chasis, J. G. Conboy, P. Gascard, Y. Takakuwa, S. C. Huang, E. J. Benz, Jr., A. Bretscher, R. G. Fehon, J. F. Gusella, V. Ramesh, F. Solomon, V. T. Marchesi, S. Tsukita, K. B. Hoover and et al.: The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci, 23(8), 281-2 (1998) (Pubitemid 28461889)
12. A. Bretscher, K. Edwards and R. G. Fehon: ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol, 3(8), 586-99 (2002)
13. A. Gautreau, P. Poullet, D. Louvard and M. Arpin: Ezrin, a plasma membrane-microfilament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A, 96(13), 7300-5 (1999) (Pubitemid 29299656)
14. F. J. Gunn-Moore, G. I. Welsh, L. R. Herron, F. Brannigan, K. Venkateswarlu, S. Gillespie, M. Brandwein-Gensler, R. Madan, J. M. Tavare, P. J. Brophy, M. B. Prystowsky and S. Guild: A novel 4.1 ezrin radixin moesin (FERM)-containing protein, 'Willin'. FEBS Lett, 579(22), 5089-94 (2005) (Pubitemid 41242858)
15. M. A. Pearson, D. Reczek, A. Bretscher and P. A. Karplus: Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell, 101(3), 259-70 (2000)
16. T. Shimizu, A. Seto, N. Maita, K. Hamada, S. Tsukita and T. Hakoshima: Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem, 277(12), 10332-6 (2002) (Pubitemid 34968150)
17. B. Garcia-Alvarez, J. M. de Pereda, D. A. Calderwood, T. S. Ulmer, D. Critchley, I. D. Campbell, M. H. Ginsberg and R. C. Liddington: Structural determinants of integrin recognition by talin. Mol Cell, 11(1), 49-58 (2003) (Pubitemid 36131107)
18. K. Hamada, T. Shimizu, S. Yonemura, S. Tsukita and T. Hakoshima: Structural basis of adhesion-molecule recognition by ERM proteins revealed by the crystal structure of the radixin-ICAM-2 complex. EMBO J, 22(3), 502-14 (2003) (Pubitemid 36193595)
19. E. J. Weinman, D. Steplock, J. B. Wade and S. Shenolikar: Ezrin binding domain-deficient NHERF attenuates cAMP-mediated inhibition of Na(+)/H(+) exchange in OK cells. Am J Physiol Renal Physiol, 281(2), F374-80 (2001)
20. A. Darmellah, C. Rucker-Martin and D. Feuvray: ERM proteins mediate the effects of Na+/H+ exchanger (NHE1) activation in cardiac myocytes. Cardiovasc Res, 81(2), 294-300 (2009)
21. T. A. Martin, G. Harrison, R. E. Mansel and W. G. Jiang: The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol, 46(2), 165-86 (2003) (Pubitemid 36452345)
22. S. Yonemura, M. Hirao, Y. Doi, N. Takahashi, T. Kondo and S. Tsukita: Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol, 140(4), 885-95 (1998) (Pubitemid 28141226)
23. D. J. Killock, M. Parsons, M. Zarrouk, S. M. Ameer-Beg, A. J. Ridley, D. O. Haskard, M. Zvelebil and A. Ivetic: In vitro and in vivo Characterization of Molecular Interactions between Calmodulin, Ezrin/Radixin/Moesin, and L-selectin. J Biol Chem, 284(13), 8833-45 (2009)
24. M. Janke, A. Herrig, J. Austermann, V. Gerke, C. Steinem and A. Janshoff: Actin binding of ezrin is activated by specific recognition of PIP2-functionalized lipid bilayers. Biochemistry, 47(12), 3762-9 (2008) (Pubitemid 351431366)
25. U. Tepass: FERM proteins in animal morphogenesis. Curr Opin Genet Dev, 19(4), 357-67 (2009)
26. J. Carlsen, K. Christiansen and B. Bro: Purification of microvillus membrane vesicles from pig small intestine by adsorption chromatography on Sepharose. Biochim Biophys Acta, 727(2), 412-5 (1983) (Pubitemid 13165896)
27. K. L. Gould, J. A. Cooper, A. Bretscher and T. Hunter: The protein-tyrosine kinase substrate, p81, is homologous to a chicken microvillar core protein. J Cell Biol, 102(2), 660-9 (1986) (Pubitemid 16140828)
28. M. R. Amieva, K. K. Wilgenbus and H. Furthmayr: Radixin is a component of hepatocyte microvilli in situ. Exp Cell Res, 210(1), 140-4 (1994) (Pubitemid 24168507)
29. W. Lankes, A. Griesmacher, J. Grunwald, R. Schwartz-Albiez and R. Keller: A heparin-binding protein involved in inhibition of smooth-muscle cell proliferation. Biochem J, 251(3), 831-42 (1988)
30. C. J. Watson, L. Gaunt, G. Evans, K. Patel, R. Harris and T. Strachan: A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. Hum Mol Genet, 2(6), 701-4 (1993) (Pubitemid 23197513)
31. D. Nowak, A. J. Mazur, A. Popow-Wozniak, A. Radwanska, H. G. Mannherz and M. Malicka-Blaszkiewicz: Subcellular distribution and expression of cofilin and ezrin in human colon adenocarcinoma cell lines with different metastatic potential. Eur J Histochem, 54(2), e14
32. D. Sarrio, S. M. Rodriguez-Pinilla, A. Dotor, F. Calero, D. Hardisson and J. Palacios: Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat, 98(1), 71-9 (2006) (Pubitemid 44050782)
33. A. Gautreau, D. Louvard and M. Arpin: ERM proteins and NF2 tumor suppressor: the Yin and Yang of cortical actin organization and cell growth signaling. Curr Opin Cell Biol, 14(1), 104-9 (2002) (Pubitemid 34131663)
34. A. Bretscher, D. Chambers, R. Nguyen and D. Reczek: ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu Rev Cell Dev Biol, 16, 113-43 (2000) (Pubitemid 32037502)
35. B. E. Elliott, J. A. Meens, S. K. SenGupta, D. Louvard and M. Arpin: The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res, 7(3), R365-73 (2005)
36. C. Khanna, X. Wan, S. Bose, R. Cassaday, O. Olomu, A. Mendoza, C. Yeung, R. Gorlick, S. M. Hewitt and L. J. Helman: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med, 10(2), 182-6 (2004) (Pubitemid 38524889)
37. Y. Yu, J. Khan, C. Khanna, L. Helman, P. S. Meltzer and G. Merlino: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med, 10(2), 175-81 (2004) (Pubitemid 38524888)
38. Y. K. Kang, S. W. Hong, H. Lee and W. H. Kim: Prognostic implications of ezrin expression in human hepatocellular carcinoma. Mol Carcinog, 49(9), 798-804 (2010)
39. A. Nestl, O. D. Von Stein, K. Zatloukal, W. G. Thies, P. Herrlich, M. Hofmann and J. P. Sleeman: Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res, 61(4), 1569-77 (2001) (Pubitemid 34292589)
40. X. Deng, S. H. Tannehill-Gregg, M. V. Nadella, G. He, A. Levine, Y. Cao and T. J. Rosol: Parathyroid hormonerelated protein and ezrin are up-regulated in human lung cancer bone metastases. Clin Exp Metastasis, 24(2), 107-19 (2007) (Pubitemid 46669244)
41. Y. Meng, Z. Lu, S. Yu, Q. Zhang, Y. Ma and J. Chen: Ezrin promotes invasion and metastasis of pancreatic cancer cells. J Transl Med, 8(1), 61
42. C. Federici, D. Brambilla, F. Lozupone, P. Matarrese, A. de Milito, L. Lugini, E. Iessi, S. Cecchetti, M. Marino, M. Perdicchio, M. Logozzi, M. Spada, W. Malorni and S. Fais: Pleiotropic function of ezrin in human metastatic melanomas. Int J Cancer, 124(12), 2804-12 (2009)
43. B. Zhou, J. Leng, M. Hu, L. Zhang, Z. Wang, D. Liu, X. Tong, B. Yu, Y. Hu, C. Deng, Y. Liu and Q. Zhang: Ezrin is a key molecule in the metastasis of MOLT4 cells induced by CCL25/CCR9. Leuk Res, 34(6), 769-76
44. K. Takahashi, T. Sasaki, A. Mammoto, K. Takaishi, T. Kameyama, S. Tsukita and Y. Takai: Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J Biol Chem, 272(37), 23371-5 (1997) (Pubitemid 27392478)
45. Y. C. Chuan, D. Iglesias-Gato, L. Fernandez-Perez, A. Cedazo-Minguez, S. T. Pang, G. Norstedt, A. Pousette and A. Flores-Morales: Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene, 29(10), 1531-42
46. F. C. Morales, J. R. Molina, Y. Hayashi and M. M. Georgescu: Overexpression of ezrin inactivates NF2 tumor suppressor in glioblastoma. Neuro Oncol, 12(6), 528-39
47. K. Endo, S. Kondo, J. Shackleford, T. Horikawa, N. Kitagawa, T. Yoshizaki, M. Furukawa, Y. Zen and J. S. Pagano: Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene, 28(14), 1725-35 (2009)
48. T. Ichikawa, J. Masumoto, M. Kaneko, T. Saida, J. Sagara and S. Taniguchi: Moesin and CD44 expression in cutaneous melanocytic tumours. Br J Dermatol, 138(5), 763-8 (1998) (Pubitemid 28231514)
49. D. Lallemand and M. Arpin: Moesin/ezrin: a specific role in cell metastasis? Pigment Cell Melanoma Res, 23(1), 6-7
50. G. Pawlak and D. M. Helfman: Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev, 11(1), 41-7 (2001) (Pubitemid 32119276)
51. X. D. Fu, M. S. Giretti, C. Baldacci, S. Garibaldi, M. Flamini, A. M. Sanchez, A. Gadducci, A. R. Genazzani and T. Simoncini: Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS One, 3(7), e2790 (2008)
52. A. M. Sanchez, M. I. Flamini, X. D. Fu, P. Mannella, M. S. Giretti, L. Goglia, A. R. Genazzani and T. Simoncini: Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol, 23(8), 1193-202 (2009)
53. X. D. Fu, M. Flamini, A. M. Sanchez, L. Goglia, M. S. Giretti, A. R. Genazzani and T. Simoncini: Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin. Mol Hum Reprod, 14(4), 225-34 (2008) (Pubitemid 351627292)
54. M. He, Y. Cheng, W. Li, Q. Liu, J. Liu, J. Huang and X. Fu: Vascular endothelial growth factor C promotes cervical cancer metastasis via up-regulation and activation of RhoA/ROCK-2/moesin cascade. BMC Cancer, 10, 170
55. A. Estecha, L. Sanchez-Martin, A. Puig-Kroger, R. A. Bartolome, J. Teixido, R. Samaniego and P. Sanchez-Mateos: Moesin orchestrates cortical polarity of melanoma tumour cells to initiate 3D invasion. J Cell Sci, 122(Pt 19), 3492-501 (2009)
56. H. Lyng, R. S. Brovig, D. H. Svendsrud, R. Holm, O. Kaalhus, K. Knutstad, H. Oksefjell, K. Sundfor, G. B. Kristensen and T. Stokke: Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics, 7, 268 (2006)
57. S. Garcia, J. P. Dales, E. Charafe-Jauffret, S. Carpentier-Meunier, L. Andrac-Meyer, J. Jacquemier, C. Andonian, M. N. Lavaut, C. Allasia, P. Bonnier and C. Charpin: Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol, 31(1), 49-58 (2007)
58. H. Kobayashi, S. Kawamoto, Y. Sakai, P. L. Choyke, R. A. Star, M. W. Brechbiel, N. Sato, Y. Tagaya, J. C. Morris and T. A. Waldmann: Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent. J Natl Cancer Inst, 96(9), 703-8 (2004) (Pubitemid 38660233)
59. E. Charafe-Jauffret, F. Monville, F. Bertucci, B. Esterni, C. Ginestier, P. Finetti, N. Cervera, J. Geneix, M. Hassanein, L. Rabayrol, H. Sobol, C. Taranger-Charpin, L. Xerri, P. Viens, D. Birnbaum and J. Jacquemier: Moesin expression is a marker of basal breast carcinomas. Int J Cancer, 121(8), 1779-85 (2007) (Pubitemid 47417297)
60. H. Kobayashi, J. Sagara, H. Kurita, M. Morifuji, M. Ohishi, K. Kurashina and S. Taniguchi: Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res, 10(2), 572-80 (2004) (Pubitemid 38173996)
61. Y. Cui, J. Wu, M. Zong, G. Song, Q. Jia, J. Jiang and J. Han: Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer, 124(7), 1614-21 (2009)
62. I. Abiatari, I. Esposito, T. De Oliveira, K. Felix, H. Xin, R. Penzel, T. Giese, H. Friess and J. Kleeff: Moesin Dependent Cytoskeleton Remodeling Is Associated with an Anaplastic Phenotype of Pancreatic Cancer. J Cell Mol Med(2009)
63. D. H. Gutmann, A. Aylsworth, J. C. Carey, B. Korf, J. Marks, R. E. Pyeritz, A. Rubenstein and D. Viskochil: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA, 278(1), 51-7 (1997) (Pubitemid 27274517)
64. D. R. Scoles: The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta, 1785(1), 32-54 (2008) (Pubitemid 350192083)
65. M. E. Sughrue, A. H. Yeung, M. J. Rutkowski, S. W. Cheung and A. T. Parsa: Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. J Neurosurg(2009)
66. K. H. Yohay: The genetic and molecular pathogenesis of NF1 and NF2. Semin Pediatr Neurol, 13(1), 21-6 (2006) (Pubitemid 43963397)
67. G. A. Rouleau, P. Merel, M. Lutchman, M. Sanson, J. Zucman, C. Marineau, K. Hoang-Xuan, S. Demczuk, C. Desmaze, B. Plougastel and et al.: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature, 363(6429), 515-21 (1993) (Pubitemid 23186636)
68. J. A. Trofatter, M. M. MacCollin, J. L. Rutter, J. R. Murrell, M. P. Duyao, D. M. Parry, R. Eldridge, N. Kley, A. G. Menon, K. Pulaski and et al.: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell, 75(4), 826 (1993)
69. A. B. Bianchi, T. Hara, V. Ramesh, J. Gao, A. J. Klein-Szanto, F. Morin, A. G. Menon, J. A. Trofatter, J. F. Gusella, B. R. Seizinger and et al.: Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet, 6(2), 185-92 (1994) (Pubitemid 24188601)
70. J. A. Trofatter, M. M. MacCollin, J. L. Rutter, J. R. Murrell, M. P. Duyao, D. M. Parry, R. Eldridge, N. Kley, A. G. Menon, K. Pulaski and et al.: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell, 72(5), 791-800 (1993) (Pubitemid 23093886)
71. O. Turunen, T. Wahlstrom and A. Vaheri: Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J Cell Biol, 126(6), 1445-53 (1994) (Pubitemid 24284609)
72. B. K. Cole, M. Curto, A. W. Chan and A. I. McClatchey: Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing. Mol Cell Biol, 28(4), 1274-84 (2008) (Pubitemid 351214130)
73. M. Gronholm, M. Sainio, F. Zhao, L. Heiska, A. Vaheri and O. Carpen: Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin. J Cell Sci, 112 (Pt 6), 895-904 (1999) (Pubitemid 29179322)
74. L. Sherman, H. M. Xu, R. T. Geist, S. Saporito-Irwin, N. Howells, H. Ponta, P. Herrlich and D. H. Gutmann: Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene, 15(20), 2505-9 (1997) (Pubitemid 27503537)
75. J. L. Kissil, E. W. Wilker, K. C. Johnson, M. S. Eckman, M. B. Yaffe and T. Jacks: Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell, 12(4), 841-9 (2003) (Pubitemid 37352778)
76. Y. K. Lau, L. B. Murray, S. S. Houshmandi, Y. Xu, D. H. Gutmann and Q. Yu: Merlin is a potent inhibitor of glioma growth. Cancer Res, 68(14), 5733-42 (2008)
77. R. J. Shaw, J. G. Paez, M. Curto, A. Yaktine, W. M. Pruitt, I. Saotome, J. P. O'Bryan, V. Gupta, N. Ratner, C. J. Der, T. Jacks and A. I. McClatchey: The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell, 1(1), 63-72 (2001) (Pubitemid 33586069)
78. M. Laulajainen, T. Muranen, O. Carpen and M. Gronholm: Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton. Oncogene, 27(23), 3233-43 (2008) (Pubitemid 351733388)
79. K. Alfthan, L. Heiska, M. Gronholm, G. H. Renkema and O. Carpen: Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization. J Biol Chem, 279(18), 18559-66 (2004) (Pubitemid 38623276)
80. A. I. McClatchey and M. Giovannini: Membrane organization and tumorigenesis-the NF2 tumor suppressor, Merlin. Genes Dev, 19(19), 2265-77 (2005) (Pubitemid 41396902)
81. D. Lallemand, A. L. Saint-Amaux and M. Giovannini: Tumor-suppression functions of merlin are independent of its role as an organizer of the actin cytoskeleton in Schwann cells. J Cell Sci, 122(Pt 22), 4141-9 (2009)
82. I. Stamenkovic and Q. Yu: Merlin, a "Magic" Linker between Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell Motility, Proliferation, and Survival. Curr Protein Pept Sci
83. N. Reed and D. H. Gutmann: Tumorigenesis in neurofibromatosis: new insights and potential therapies. Trends Mol Med, 7(4), 157-62 (2001) (Pubitemid 32280374)
84. A. I. McClatchey, I. Saotome, K. Mercer, D. Crowley, J. F. Gusella, R. T. Bronson and T. Jacks: Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev, 12(8), 1121-33 (1998) (Pubitemid 28194048)
85. D. Lallemand, M. Curto, I. Saotome, M. Giovannini and A. I. McClatchey: NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev, 17(9), 1090-100 (2003) (Pubitemid 36534984)
86. A. M. Bashour, J. J. Meng, W. Ip, M. MacCollin and N. Ratner: The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol, 22(4), 1150-7 (2002) (Pubitemid 34094851)
87. N. Manchanda, A. Lyubimova, H. Y. Ho, M. F. James, J. F. Gusella, N. Ramesh, S. B. Snapper and V. Ramesh: The NF2 tumor suppressor Merlin and the ERM proteins interact with N-WASP and regulate its actin polymerization function. J Biol Chem, 280(13), 12517-22 (2005)
88. P. D. Pelton, L. S. Sherman, T. A. Rizvi, M. A. Marchionni, P. Wood, R. A. Friedman and N. Ratner: Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene, 17(17), 2195-209 (1998) (Pubitemid 28515373)
89. P. I. Poulikakos, G. H. Xiao, R. Gallagher, S. Jablonski, S. C. Jhanwar and J. R. Testa: Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene, 25(44), 5960-8 (2006) (Pubitemid 44477290)
90. M. Giovannini, E. Robanus-Maandag, M. van der Valk, M. Niwa-Kawakita, V. Abramowski, L. Goutebroze, J. M. Woodruff, A. Berns and G. Thomas: Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev, 14(13), 1617-30 (2000) (Pubitemid 30460911)
91. M. E. Baser, A. De Rienzo, D. Altomare, B. R. Balsara, N. M. Hedrick, D. H. Gutmann, L. H. Pitts, R. K. Jackler and J. R. Testa: Neurofibromatosis 2 and malignant mesothelioma. Neurology, 59(2), 290-1 (2002) (Pubitemid 34779196)
92. M. Curto, B. K. Cole, D. Lallemand, C. H. Liu and A. I. McClatchey: Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol, 177(5), 893-903 (2007) (Pubitemid 46873094)
93. C. Thurneysen, I. Opitz, S. Kurtz, W. Weder, R. A. Stahel and E. Felley-Bosco: Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer, 64(2), 140-7 (2009)
94. C. O. Hanemann: Magic but treatable? Tumours due to loss of merlin. Brain, 131(Pt 3), 606-15 (2008) (Pubitemid 351294705)
95. Z. Galcheva-Gargova, N. Zhidkova, S. Geisler, J. Ozug, S. Wudyka, N. S. Gunay, Y. W. Qi, Z. Shriver and G. Venkataraman: Overexpression of Merlin in B16F10 mouse melanoma cells reduces their metastatic activity: role of the cell surface heparan sulfate glycosaminoglycans. Int J Oncol, 32(6), 1237-43 (2008)
96. C. Flaiz, S. Ammoun, A. Biebl and C. O. Hanemann: Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma. Brain Pathol, 19(1), 27-38 (2009)
97. S. Y. Wong, H. Haack, J. L. Kissil, M. Barry, R. T. Bronson, S. S. Shen, C. A. Whittaker, D. Crowley and R. O. Hynes: Protein 4.1B suppresses prostate cancer progression and metastasis. Proc Natl Acad Sci U S A, 104(31), 12784-9 (2007) (Pubitemid 47255232)
98. M. Parra, P. Gascard, L. D. Walensky, J. A. Gimm, S. Blackshaw, N. Chan, Y. Takakuwa, T. Berger, G. Lee, J. A. Chasis, S. H. Snyder, N. Mohandas and J. G. Conboy: Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain. J Biol Chem, 275(5), 3247-55 (2000) (Pubitemid 30083025)
99. Y. K. Tran, O. Bogler, K. M. Gorse, I. Wieland, M. R. Green and I. F. Newsham: A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res, 59(1), 35-43 (1999) (Pubitemid 29062951)
100. J. G. Conboy: Structure, function, and molecular genetics of erythroid membrane skeletal protein 4.1 in normal and abnormal red blood cells. Semin Hematol, 30(1), 58-73 (1993) (Pubitemid 23060460)
101. D. H. Gutmann, A. C. Hirbe, Z. Y. Huang and C. A. Haipek: The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis, 8(2), 266-78 (2001) (Pubitemid 32382480)
102. D. H. Gutmann, J. Donahoe, A. Perry, N. Lemke, K. Gorse, K. Kittiniyom, S. A. Rempel, J. A. Gutierrez and I. F. Newsham: Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet, 9(10), 1495-500 (2000) (Pubitemid 30386704)
103. A. L. Charboneau, V. Singh, T. Yu and I. F. Newsham: Suppression of growth and increased cellular attachment after expression of DAL-1 in MCF-7 breast cancer cells. Int J Cancer, 100(2), 181-8 (2002) (Pubitemid 34666192)
104. M. A. Gerber, S. M. Bahr and D. H. Gutmann: Protein 4.1B/differentially expressed in adenocarcinoma of the lung-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent c-Jun-NH(2)-kinase signaling. Cancer Res, 66(10), 5295-303 (2006) (Pubitemid 43844954)
105. J. H. McCarty, A. A. Cook and R. O. Hynes: An interaction between {alpha}v{beta}8 integrin and Band 4.1B via a highly conserved region of the Band 4.1 Cterminal domain. Proc Natl Acad Sci U S A, 102(38), 13479-83 (2005) (Pubitemid 41420873)
106. Y. Hashimoto, N. Shindo-Okada, M. Tani, K. Takeuchi, H. Toma and J. Yokota: Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display. Cancer Res, 56(22), 5266-71 (1996) (Pubitemid 26383046)
107. K. Shimizu, Y. Nagamachi, M. Tani, K. Kimura, T. Shiroishi, S. Wakana and J. Yokota: Molecular cloning of a novel NF2/ERM/4.1 superfamily gene, ehm2, that is expressed in high-metastatic K1735 murine melanoma cells. Genomics, 65(2), 113-20 (2000) (Pubitemid 30314418)
108. S. Chauhan, R. Pandey, J. F. Way, T. C. Sroka, M. C. Demetriou, S. Kunz, A. E. Cress, D. W. Mount and R. L. Miesfeld: Androgen regulation of the human FERM domain encoding gene EHM2 in a cell model of steroidinduced differentiation. Biochem Biophys Res Commun, 310(2), 421-32 (2003) (Pubitemid 37163681)
109. S. Chauhan, S. Kunz, K. Davis, J. Roberts, G. Martin, M. C. Demetriou, T. C. Sroka, A. E. Cress and R. L. Miesfeld: Androgen control of cell proliferation and cytoskeletal reorganization in human fibrosarcoma cells: role of RhoB signaling. J Biol Chem, 279(2), 937-44 (2004) (Pubitemid 38082614)
110. J. Wang, Y. Cai, R. Penland, S. Chauhan, R. L. Miesfeld and M. Ittmann: Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate, 66(15), 1641-52 (2006) (Pubitemid 44646355)
111. K. B. Hoover and P. J. Bryant: Drosophila Yurt is a new protein-4.1-like protein required for epithelial morphogenesis. Dev Genes Evol, 212(5), 230-8 (2002) (Pubitemid 36067676)
112. H. F. Yu, L. Ye, Y. U. Zhang, W. G. Jiang. Ehm2 influences the aggressiveness of breast cancer cells through regulation of MMP-9 expression, and aberrant expression of Ehm2 correlates with disease progression in breast cancer. Cancer Res, in press (2010)
113. H. F. Yu, L. Ye, Y. U. Zhang, R. E. Mansel, W. G. Jiang. EHM2 influences the aggressiveness of breast cancer cells through regulation of MMP-9 expression, and the clinical implications. Mol Cancer Res, in press (2011)
114. L. M. Chen, D. Bailey and C. Fernandez-Valle: Association of beta 1 integrin with focal adhesion kinase and paxillin in differentiating Schwann cells. J Neurosci, 20(10), 3776-84 (2000) (Pubitemid 30266239)
115. P. Poullet, A. Gautreau, G. Kadare, J. A. Girault, D. Louvard and M. Arpin: Ezrin interacts with focal adhesion kinase and induces its activation independently of cellmatrix adhesion. J Biol Chem, 276(40), 37686-91 (2001)
116. R. Chen, O. Kim, M. Li, X. Xiong, J. L. Guan, H. J. Kung, H. Chen, Y. Shimizu and Y. Qiu: Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain. Nat Cell Biol, 3(5), 439-44 (2001) (Pubitemid 32422078)
117. S. Y. Chen and H. C. Chen: Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol, 26(13), 5155-67 (2006)
118. D. J. Sieg, C. R. Hauck, D. Ilic, C. K. Klingbeil, E. Schaefer, C. H. Damsky and D. D. Schlaepfer: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol, 2(5), 249-56 (2000)
119. D. Lietha, X. Cai, D. F. Ceccarelli, Y. Li, M. D. Schaller and M. J. Eck: Structural basis for the autoinhibition of focal adhesion kinase. Cell, 129(6), 1177-87 (2007) (Pubitemid 46891044)
120. S. K. Mitra and D. D. Schlaepfer: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol, 18(5), 516-23 (2006) (Pubitemid 44332916)
121. Z. Xing, H. C. Chen, J. K. Nowlen, S. J. Taylor, D. Shalloway and J. L. Guan: Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell, 5(4), 413-21 (1994) (Pubitemid 24178320)
122. R. E. Gates, L. E. King, Jr., S. K. Hanks and L. B. Nanney: Potential role for focal adhesion kinase in migrating and proliferating keratinocytes near epidermal wounds and in culture. Cell Growth Differ, 5(8), 891-9 (1994) (Pubitemid 24258996)
123. T. M. Weiner, E. T. Liu, R. J. Craven and W. G. Cance: Expression of focal adhesion kinase gene and invasive cancer. Lancet, 342(8878), 1024-5 (1993) (Pubitemid 23314806)
124. T. Akasaka, R. L. van Leeuwen, I. G. Yoshinaga, M. C. Mihm, Jr. and H. R. Byers: Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines. J Invest Dermatol, 105(1), 104-8 (1995)
125. W. G. Cance, J. E. Harris, M. V. Iacocca, E. Roche, X. Yang, J. Chang, S. Simkins and L. Xu: Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. Clin Cancer Res, 6(6), 2417-23 (2000) (Pubitemid 30399210)
126. L. Tremblay, W. Hauck, A. G. Aprikian, L. R. Begin, A. Chapdelaine and S. Chevalier: Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma. Int J Cancer, 68(2), 164-71 (1996) (Pubitemid 26380117)
127. J. S. Chen, X. H. Huang, Q. Wang, X. L. Chen, X. H. Fu, H. X. Tan, L. J. Zhang, W. Li and J. Bi: FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis, 27(2), 71-82
128. V. G. Brunton, E. Avizienyte, V. J. Fincham, B. Serrels, C. A. Metcalf, 3rd, T. K. Sawyer and M. C. Frame: Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res, 65(4), 1335-42 (2005) (Pubitemid 40270160)
129. H. R. Reiske, S. C. Kao, L. A. Cary, J. L. Guan, J. F. Lai and H. C. Chen: Requirement of phosphatidylinositol 3-kinase in focal adhesion kinase-promoted cell migration. J Biol Chem, 274(18), 12361-6 (1999)
130. X. N. Meng, Y. Jin, Y. Yu, J. Bai, G. Y. Liu, J. Zhu, Y. Z. Zhao, Z. Wang, F. Chen, K. Y. Lee and S. B. Fu: Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer, 101(2), 327-34 (2009)
131. T. Kaneda, Y. Sonoda, K. Ando, T. Suzuki, Y. Sasaki, T. Oshio, M. Tago and T. Kasahara: Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis. Cancer Lett, 270(2), 354-61 (2008)
132. S. Sakamoto, R. O. McCann, R. Dhir and N. Kyprianou: Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res, 70(5), 1885-95
133. C. A. Lipinski, N. L. Tran, E. Menashi, C. Rohl, J. Kloss, R. C. Bay, M. E. Berens and J. C. Loftus: The tyrosine kinase pyk2 promotes migration and invasion of glioma cells. Neoplasia, 7(5), 435-45 (2005) (Pubitemid 40791863)
134. E. H. van der Horst, I. Weber and A. Ullrich: Tyrosine phosphorylation of PYK2 mediates heregulininduced glioma invasion: novel heregulin/HER3-stimulated signaling pathway in glioma. Int J Cancer, 113(5), 689-98 (2005) (Pubitemid 40101248)
135. J. C. Loftus, Z. Yang, N. L. Tran, J. Kloss, C. Viso, M. E. Berens and C. A. Lipinski: The Pyk2 FERM domain as a target to inhibit glioma migration. Mol Cancer Ther, 8(6), 1505-14 (2009)